First Person Officially Allowed To Prescribe Medical Cannabis In Australia Says System Now Being Routinely Rorted | Cannabis Law Report | How to buy Skittles Moonrock online

Learn how to buy Skittles Moonrock online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

RACGP

Associate Professor Vicki Kotsirilos was at the vanguard of changes surrounding the prescription of medicinal cannabis.

In 2018, she became Australia’s first authorised GP prescriber and welcomed the broadening of treatment options for the right type of patient when other clinical options have been exhausted.

But as prescription rates continue to skyrocket – driven by high-volume telehealth prescriptions – her unease has grown.

That was brought into focus by the latest ‘Cannabis in Australia’ report from the Penington Institute, a Melbourne-based public health research organisation, which highlighted a huge leap in sales in the past year.

It published data provided by companies to the Therapeutic Goods Administration (TGA), showing 2.87 million units sold in the first six months of 2024 – a huge climb on the 1.68 million recorded in the second half of 2023.

It also estimates Australians spent around $402 million on medicinal cannabis prescriptions from January to the end of June this year.

The total for all of 2023 was estimated at $448 million, which itself was a big leap from $234 million in 2022, with the report indicating the market for illicit cannabis stands at around $5 billion annually.

‘The high-volume access of medicinal cannabis products by clinics set up solely for prescribing these products deeply concerns me,’ Associate Professor Kotsirilos told newsGP.

For her, a particular issue is companies selling their products directly to consumers, including via telehealth or other means.

‘This set up presents a significant conflict of interest – it is modelled around prescribing high volumes of medicinal cannabis products on demand for profit,’ she said.

‘Federal Government laws and tighter regulations must urgently be introduced to stop this model of dispensing.’

The Penington Institute, which argues that general cannabis supply should be decriminalised but strictly regulated, reaches a similar conclusion.

‘Some medicinal cannabis clinics are clearly prioritising high-volume access over high-quality medical care,’ its report states.

The Institute’s CEO, John Ryan, said while there are ‘legitimate concerns’ about the conduct and sales methods of a small number of medicinal cannabis companies, ‘most operators in the space conducted themselves ethically and professionally’.

Source: https://www1.racgp.org.au/newsgp/clinical/deeply-concerns-me-original-prescriber-s-alarm-ove